Drugs Made In America Acquisition Corp.(DMAA)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
DMAA Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Drugs Made In America Acquisition Corp. (DMAA), a Financials sector company. DMAA is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), Drugs Made In America Acquisition Corp. reports net income of $2.0M, free cash flow of $-91.3K. Top institutional holders of DMAA by reported 13-F value include Karpus Management,, First Capital Management L.P., MIZUHO SECURITIES USA, based on the most recent SEC filings. DMAA trades on the Nasdaq exchange and files with the SEC under CIK 2028614. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate DMAA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Drugs Made In America Acquisition Corp. directly from SEC EDGAR.
Net Income
Q1 2026
$2.0M
Free Cash Flow
Q1 2026
$-91.3K
AI Insight: DMAA Financial Trends
DMAA remains a cash-burn shell with negative equity and no revenue visibility across six quarters.
• Net income oscillated between $0–2M across six quarters with no discernible trend; operating income remained negative or flat.
• Equity stuck at –$7M from Q1 2025 through Q1 2026, indicating persistent liabilities exceed assets with no improvement.
⚠ No revenue reported across entire dataset; company appears inactive or pre-revenue acquisition vehicle.
⚠ Operating cash flow consistently at or near zero; no capital deployment or operational activity evident.
AI Insight: DMAA Ratio Trends
Asset returns collapsed to 0.4% in Q4 2025 before rebounding to 3.3% in Q1 2026, signaling severe operational distress or accounting anomaly.
• ROA fell sharply to 0.4% in Q4 2025, the lowest point in the dataset, then recovered to 3.3% in Q1 2026.
• TTM ROA stands at 2.8%, below most quarterly readings except Q4 2025, indicating weak overall asset productivity.
⚠ Q4 2025 ROA collapse unexplained by available data—investigate one-time charges, accounting changes, or operational disruptions.
⚠ Only ROA metrics available; OpMargin, NPM, ROE, ROIC, and leverage ratios all missing—limits visibility into profitability and capital structure.
Get alerted when DMAA's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Drugs Made In America Acquisition Corp. including:
Top Institutional Holders of DMAA
Karpus Management, Inc.
$26.5M2,530,517 shFirst Trust Capital Management L.P.
$23.5M2,242,500 shMIZUHO SECURITIES USA LLC
$20.9M2,000,000 shWestchester Capital Management, LLC
$17.5M1,669,000 shPolar Asset Management Partners Inc.
$16.8M1,600,000 shWOLVERINE ASSET MANAGEMENT LLC
$16.3M1,553,708 shHIGHBRIDGE CAPITAL MANAGEMENT LLC
$13.9M1,323,351 shJPMORGAN CHASE & CO
$13.9M1,323,351 shARISTEIA CAPITAL, L.L.C.
$9.2M881,716 shD. E. Shaw & Co., Inc.
$7.2M690,000 sh
| Fund | Value | Shares |
|---|---|---|
| Karpus Management, Inc. | $26.5M | 2,530,517 |
| First Trust Capital Management L.P. | $23.5M | 2,242,500 |
| MIZUHO SECURITIES USA LLC | $20.9M | 2,000,000 |
| Westchester Capital Management, LLC | $17.5M | 1,669,000 |
| Polar Asset Management Partners Inc. | $16.8M | 1,600,000 |
| WOLVERINE ASSET MANAGEMENT LLC | $16.3M | 1,553,708 |
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | $13.9M | 1,323,351 |
| JPMORGAN CHASE & CO | $13.9M | 1,323,351 |
| ARISTEIA CAPITAL, L.L.C. | $9.2M | 881,716 |
| D. E. Shaw & Co., Inc. | $7.2M | 690,000 |
More Financials Companies
View all Financials →Put DMAA on your watchlist
Track score changes the day Drugs Made In America Acquisition Corp. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is DMAA a good stock to buy?
13F Pro's AI-powered analysis of Drugs Made In America Acquisition Corp. (DMAA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Financials sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for DMAA are available on the DMAA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own DMAA?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling DMAA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Drugs Made In America Acquisition Corp.'s investment landscape.